Status:
RECRUITING
ATG Individualized Dosing Model in URD-PBSCT.
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Cytomegalovirus Infections
Infection Reactivation
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
Brief Summary
Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG ma...
Detailed Description
Allogeneic hematopoietic cell transplantation(allo-HCT) is a curative therapy for hematological disorders and the ATG is commonly used as prophylaxis for GVHD. Previous studies have indicated that the...
Eligibility Criteria
Inclusion
- Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation.
- HLA-matched unrelated donor
- Patient age ≥14 years old and ≤65 years old
- ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values
- Creatinine ≤ high limit of normal value
- No uncontrollable infection or serious mental illness
- Physical strength score is 0-2 (ECOG)
- Sign the informed consent form
Exclusion
- Unrelated donor who is not HLA matched
- No indication for allogeneic hematopoietic stem cell transplantation
- Patient age \<14 years old or \>65 years old
- The donor or recipient are pregnant
- Suffering from mental illness or other conditions and being unable to proceed as planned
Key Trial Info
Start Date :
December 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06572462
Start Date
December 31 2020
End Date
June 30 2025
Last Update
December 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, First Medical Center of Chinese PLA General Hospital
Beijing, China